GENELUX CORP: directors' dealings · United States · SEC (Form 4) Explore the full directors' dealings record of GENELUX CORP, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €136.8m. The latest transaction was disclosed on 13 May 2025 (Cession). Among the most active insiders: Szalay Aladar. The full history is openly available.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Last declaration on 13 May 2025
All Executives107 Thresholds0 Prospectus0 Other0
Declarations 107 total
▼ Head of Regulatory · Executives · 12 May 2025
1,259 shares @ US$2.92 11.3% of flow Common Stock SEC:0001415889-25-012805:0
▼ President and CEO · Executives · 12 May 2025
10,764 shares @ US$2.92 11.7% of flow Common Stock SEC:0001415889-25-012808:0
▼ VP, Clinical Trial Operations · Executives · 12 May 2025
5,579 shares @ US$2.92 0.7% of flow Common Stock SEC:0001415889-25-012807:0
▼ General Counsel · Executives · 12 May 2025
4,475 shares @ US$2.92 15.6% of flow Common Stock SEC:0001415889-25-012809:0
▼ VP, Pharmaceutical Development · Executives · 12 May 2025
4,737 shares @ US$2.92 12.8% of flow Common Stock SEC:0001415889-25-012806:0
◆ VP, Pharmaceutical Development · Executives · 14 Mar 2025
13,350 shares 0Common Stock SEC:0001415889-25-010880:0
◆ VP, Clinical Trial Operations · Executives · 14 Mar 2025
13,350 shares 0Common Stock SEC:0001415889-25-010879:0
◆ President and CEO · Executives · 14 Mar 2025
30,339 shares 0Common Stock SEC:0001415889-25-010877:0
◆ Head of Regulatory · Executives · 14 Mar 2025
4,172 shares 0Common Stock SEC:0001415889-25-010881:0
◆ General Counsel · Executives · 14 Mar 2025
10,708 shares 0Common Stock SEC:0001415889-25-010878:0
▼ Director · Executives · 30 Dec 2024
3,460 shares @ US$2.46 10.2% of flow Common Stock SEC:0001415889-24-030248:0
◆ Head of Regulatory · Executives · 18 Dec 2024
15,525 shares 0Common Stock SEC:0001415889-24-030007:0
◆ VP, Pharmaceutical Development · Executives · 18 Dec 2024
29,000 shares 0Common Stock SEC:0001415889-24-030004:0
◆ VP, Clinical Trial Operations · Executives · 18 Dec 2024
29,000 shares 0Common Stock SEC:0001415889-24-030005:0
◆ Chief Financial Officer · Executives · 18 Dec 2024
41,650 shares 0Common Stock SEC:0001415889-24-030003:0
◆ General Counsel · Executives · 18 Dec 2024
22,000 shares 0Common Stock SEC:0001415889-24-030006:0
◆ President and CEO · Executives · 18 Dec 2024
134,500 shares 0Common Stock SEC:0001415889-24-030002:0
▼ Chief Financial Officer · Executives · 16 Dec 2024
2,103 shares @ US$2.34 100.0% of flow Common Stock SEC:0001415889-24-029744:0
▼ President and CEO · Executives · 16 Dec 2024
14,315 shares @ US$2.34 13.1% of flow Common Stock SEC:0001415889-24-029745:0
▼ Head of Regulatory · Executives · 16 Dec 2024
2,510 shares @ US$2.34 19.1% of flow Common Stock SEC:0001415889-24-029743:0
▼ VP, Pharmaceutical Development · Executives · 16 Dec 2024
6,300 shares @ US$2.34 14.4% of flow Common Stock SEC:0001415889-24-029742:0
31,777 shares @ US$2.7294 1.4% of flow Common Stock SEC:0001415889-24-023393:0
▼ Director · Executives · 11 Sept 2024
1,730 shares @ US$2.6005 5.1% of flow Common Stock SEC:0001415889-24-023335:0
23,383 shares @ US$2.7028 1.0% of flow Common Stock SEC:0001415889-24-023254:0
42,818 shares @ US$2.0929 1.5% of flow Common Stock SEC:0001415889-24-023023:0
25 of 107 declarations
Load more (82 remaining)